Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | FLT3 | P36888 | 7/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 10/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790881 | 0.91 | KDR (0.54) | KDRFLT3RAF1PDGFRBKIT | |
| SCHEMBL2791308 | 0.88 | BRAF (0.62) | KDRFLT3KITBRAFMAPK14 | |
| SCHEMBL2790878 | 0.86 | FLT3 (0.53) | KDRFLT3RAF1PDGFRBKIT | |
| SCHEMBL2792468 | 0.85 | FLT3 (0.57) | KDRFLT3RAF1PDGFRBKIT | |
| SCHEMBL2792455 | 0.82 | FLT3 (0.54) | KDRFLT3RAF1PDGFRBKIT | |
| SCHEMBL2795128 | 0.81 | FLT3 (0.55) | KDRFLT3RAF1PDGFRBKIT | |
| SCHEMBL13229710 | 0.81 | KDR (0.46) | KDRRAF1BRAFRET | |
| SCHEMBL2791297 | 0.80 | FLT3 (0.53) | KDRFLT3RAF1PDGFRBKIT | |
| SCHEMBL2791845 | 0.79 | FLT3 (0.53) | KDRFLT3RAF1PDGFRBKIT | |
| SCHEMBL2793381 | 0.79 | FLT3 (0.51) | KDRFLT3RAF1PDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921078-B1 | MULTIKINASE INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-8299252-B2 | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100168430-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1921078-A1 | MULTIKINASE INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168430-A1 | MULTIKINASE INHIBITOR | REN, RAF1, CHUK | KDR 330/4885FLT3 217/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.